CRISPR/Cas9-mediated target validation of the Splicing Inhibitor Pladienolide B
KAUST DepartmentBiological and Environmental Sciences and Engineering (BESE) Division
Desert Agriculture Initiative
Laboratory for Genome Engineering
Plant Science Program
Online Publication Date2016-02-25
Print Publication Date2016-12
Permanent link to this recordhttp://hdl.handle.net/10754/600212
MetadataShow full item record
AbstractCRISPR/Cas9 system confers molecular immunity in archeal and bacterial species against invading foreign nucleic acids. CRISPR/Cas9 system is used for genome engineering applications across diverse eukaryotic species. In this study, we demonstrate the utility of the CRISPR/Cas9 genome engineering system for drug target validation in human cells. Pladienolide B is a natural macrolide with antitumor activities mediated through the inhibition of pre-mRNA splicing. To validate the spliceosomal target of Pladienolide B, we employed the CRSIPR/Cas9 system to introduce targeted mutations in the subunits of the SF3B complex in the HEK293T cells. Our data reveal that targeted mutagenesis of the SF3b1 subunit exhibited higher levels of resistance to Pladienolide B. Therefore, our data validate the spliceosomal target of Pladienolide B and provide a proof of concept on using the CRISPR/Cas9 system for drug target identification and validation.
CitationCRISPR/Cas9-mediated target validation of the Splicing Inhibitor Pladienolide B 2016 Biochimie Open
SponsorsWe thank the Bioscience Core Facility at King Abdullah University of Science and Technology (KAUST) for technical assistance. We also thank the members of the genome engineering group at KAUST for their helpful discussions and technical assistance throughout the preparation of the manuscript. This research was funded King Abdullah University of Science and Technology (KAUST).